Can circulating biomarkers identify heart failure patients at low risk?

European Journal of Heart Failure

Volumn 17, Issue 12, 2015, Pages 1213-1215

  Richards, A Mark ^a,b   Frampton, Chris M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; ERYTHROPOIETIN; GALECTIN 3; TROPONIN I; TUMOR NECROSIS FACTOR RECEPTOR ALPHA 1A; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HOSPITAL READMISSION; HUMAN; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; RISK;

BIOMARKERS; HEART FAILURE; HUMANS; RISK;

EID: 84949508638     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.438     Document Type: Note

References (18)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: 147-239.
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
3. Meijers WC, de Boer RA, van Veldhuisen DJ, Jaarsma T, Hillege HL, Maisel AS, di Somma S, Voors AA, Peacock WF,. Biomarkers and low risk in heart failure? Data from COACH and TRIUMPH. Eur J Heart Fail 2015; 17: XXX-XXX.
4. Alla F, Zannad F, Filippatos G,. Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12: 91-95.
5. Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, Normand SL, Schreiner G, Spertus JA, Vidan MT, Wang Y, Wang Y, Krumholz HM,. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail 2010; 3: 97-103.
6. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, Flaws D, Hammett CJ, Beam DM, Ardagh MW, Troughton R, Brown AFT, George P, Kline JA, Peacock WF, Maisel AS, Richards AM,. A 2-hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker (ADAPT). J Am Coll Cardiol 2012; 59: 2091-2098.
7. Cullen L, Mueller C, Parsonage WA, Wildi K, Greenslade JH, Twerenbold R, Aldous S, Meller B, Tate JR, Reichlin T, Hammett CJ, Zellweger C, Ungerer JPJ, Gimenez MR, Troughton R, Murray K, Brown AFT, Mueller M, George P, Mosimann T, Flaws DF, Reiter M, Lamanna A, Haaf P, Pemberton CJ, Richards AM, Chu K, Reid CM, Peacock WF, Jaffe AS, Florkowski C, Deely JM, Than M,. Validation of high-sensitivity troponin I in a 2-h diagnostic strategy to assess 30-day outcomes in emergency-department patients with possible acute coronary syndrome. J Am Coll Cardiol 2013; 62: 1242-9124.
8. Than M, Aldous S, Jane Lord S, Goodacre S, Frampton CMA, Troughton R, George P, Florkowski CM, Ardagh M, Smyth D, Jardine DL, Peacock WF, Young J, Hamilton G, Deely JM, Cullen L, Richards AM,. A 2-hour diagnostic pathway for possible cardiac chest pain in the emergency department: a randomized controlled trial. JAMA Intern Med 2014; 174: 51-58.
9. Jaarsma T, van der Wal MHL, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJA, Dunselman PHJM, Tijssen JGP, HIllege HL, van Veldhuisen DJ, for the Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure. Arch Intern Med 2008; 168: 316-324.
10. Postmus D, van Veldhuisen DJ, Jaarsma T, Luttick ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL,. The COACH Risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail 2012; 14: 168-175.
11. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM,. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-3128.
12. De Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr., State of the art: newer biomarkers in heart failure. Eur J Heart Fail 2015; 17: 559-569.
13. Lin Y-H, Lin L-Y, Wu Y-W, Chien K-L, Lee C-M, Hsu R-B, Chao C-L, Wang S-S, Hsein Y-C, Liao L-C, Ho Y-L, Chen M-F,. The relationship between serum galectin-3 and serum markers of extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009; 409: 96-99.
14. Lopez B, Gonzalez A, Querejeta R, Zubillaga E, Larman M, Diez J,. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 2015; 17: 385-392.
15. De Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B,. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15: 1095-101.
16. Meijers WC, Januzzi JL, de Filippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA,. Elevated plasma G galectin-3 is associated with near-term rehospitalization in heart failure: a pooled anlaysis of 3 clinical trials. Am Heart J 2014; 167: 853-860.
17. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Dungen H-D, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM,. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 2015; 17: 214-223.
18. Chen A, Hou W, Zhang Y, Chen Y, He B,. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol 2015; 182: 168-70.